ARCHIVES

Groups Point to NCI Restrictions As Source Of Problems, Discuss Prioritizing Trials

This article is from The Cancer Letter archive.

Vol. 29 No. 28 | July 11, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI’s Katz Named Director, Arthritis Institute; Hayden Promoted At Bristol-Myers Squibb

July 14, 1995

FDA: Oncology Division Director Delap Promoted In Agency

May 29, 1998

NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer

August 26, 2005

Dugan Head ACCC, Yarbro President Elects; Amos Honored

March 18, 1983

Freireich’s Seven Laws To Protect Against Obstacles To Clinical Research

May 14, 1976

Clinical Trials: Breast Cancer Prevention Trial requires Fewer Participants, NCI Says

September 6, 1996